2022 Clinical Trials Safety Topical 
Cannabis Law Report
MAY 29, 2022
Celebrated author Michael Pollan has published two bestselling books on the topic: How to Change Your Mind and This is Your Mind on Plants. Clinical Trials and Human Subject Protections. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects. 1] Letter from Sens.
Cannabis Law Report
FEBRUARY 28, 2022
20 February 2022. Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Essay by I. war on drugs. 15 × 15.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
OCTOBER 29, 2021
(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. During the six months ended September 30, 2021, the Company raised approximately $4.1
Cannabis Law Report
DECEMBER 2, 2021
These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). You can contact Brett Mulligan at ? info@gl-lg.com ? or 503-488-5424.
The Cannigma
DECEMBER 12, 2022
Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.
Cannabis Law Report
DECEMBER 20, 2021
First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS
Project CBD
FEBRUARY 28, 2023
Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. The labs analyzed 35 oils, 40 topical products, 40 edibles, 22 beverages, 55 pet products, and 29 coffee or tea products.
Expert insights. Personalized for you.
52 
Let's personalize your content